Dr. Channing J. Paller, M.D.

Clinical Trials

• A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
• Dose Escalating Trial of Mistletoe Extract in Patients With Advanced Solid Tumors
• Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC
• Study of TGF-? Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Media Releases

From Lab to Bedside: A Renowned Oncologist’s Pioneering Work in Cancer Research and Patient Well-Being

Dr. Channing J. Paller stands at the forefront of the medical oncology field, embodying a tireless dedication to pioneering research and compassionate patient care. With a focus on urological cancers, including prostate, bladder, kidney, and testicular cancer, her profound expertise and empathetic approach have significantly impacted the lives of countless patients.

Currently holding the position of Director of Prostate Cancer Clinical Research at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland, Dr. Paller also serves as an Associate Professor of Oncology at The Johns Hopkins University School of Medicine. Her clinical practice is based at the Prostate Cancer Multidisciplinary Clinic at Sibley Memorial Hospital in Washington, D.C., where she continues to make a positive difference in the lives of her patients.

As a committed advocate for clinical research, Dr. Paller also fulfills the role of Associate Director of Oncology for The Johns Hopkins Clinical Research Network, furthering the reach and impact of innovative cancer research within the community.

A key figure in the fight against prostate cancer, Dr. Paller plays a pivotal role on the Executive Committee for the DOD-funded Prostate Cancer Clinical Trial Consortium. She is also the co-Principal Investigator for the PROMISE registry, offering genetic testing and counseling services to 5000 men with prostate cancer in the United States. This initiative not only provides crucial support to men with genetic mutations but also offers educational resources and clinical trial opportunities through Prostatecancerpromise.org. 

Dr. Paller’s journey to becoming a distinguished oncologist began with her Medical Degree from Harvard Medical School in 2005, followed by a residency in internal medicine and a fellowship in hematology and oncology at The Johns Hopkins University School of Medicine in 2008 and 2012, respectively. Her commitment to excellence led her to seek diverse experiences, including rotations at esteemed institutions such as the National Cancer Institute (NCI) Cancer Therapy Evaluation Program and the Food and Drug Administration, where she honed her skills in investigational drug assessment and regulatory science.

Board certified in medical oncology and internal medicine by the American Board of Internal Medicine, Dr. Paller’s dedication to advancing cancer care standards is evident in her active membership in prestigious organizations such as the American Society of Clinical Oncology and the American Association for Cancer Research. Through her involvement, she remains at the forefront of oncology advancements, continuously striving to enhance patient outcomes and elevate the quality of care provided.

In 2016, Dr. Paller was honored as one of only five oncologists nationwide to receive the prestigious NCI Mentored Patient-Oriented Research Career Development Award, a testament to her exceptional potential in shaping the future of cancer care. 

Prior to this, her groundbreaking contributions were acknowledged with the 2015 Passano Clinician Scientist Award, celebrating her early-stage research that has already begun to leave an indelible mark on the scientific community. Dr. Paller’s remarkable achievements were further underscored by prestigious accolades such as the 2011-2012 Young Investigator Award by the American Society of Clinical Oncology and the 2011-12 Eastern Cooperative Oncology Group Paul Carbone Award, highlighting her promise as a trailblazer in the field. She has received grant funding from the National Institutes of Health, Department of Defense, Prostate Cancer Foundation, and multiple other foundations.

Most recently, Dr. Paller has collaborated with VA leadership to establish PROFOUND-VET, a network dedicated to leveraging data to enhance care guidelines and services for Veterans. Through her unwavering commitment to advancing oncology research and patient care, she continues to make a lasting impact on the field of medical oncology.

Recommended Articles

• Innovative New Technique Improves Breast Cancer Diagnosis

  Despite only using a conventional optical microscope, researchers have found a way to see farther and more detailed into what they are studying. This is by using expansion microscopy, expanding the size of what they are observing, instead of intensifying the microscope at a high cost. This technique...

• More Evidence Found that Links Alcohol Consumption and Breast Cancer

  It has sometimes been recommended for women to drink a serving of alcohol today for their health. Specifically, one drink per day may help with a woman’s chances of preventing heart disease and may even help reduce the risk of diabetes.However, that one drink, be it a can of beer or glass of wine,...

• Woman with Breast Cancer Gets Wedding Wish Hours Before Passing Away

  A woman's wedding day is supposed to be the most magical day of her life, and this was certainly still the case for Heather Mosher. Unfortunately, the very next day the breast cancer she had been battling would take her.Heather and DavidIn May of 2015, Heather and David met in a swing dance class....

• Lymphoma: Coping with Radiation Treatment

  Getting a diagnosis of lymphoma or any type of cancer is always difficult and overwhelming. Apart from the medical aspects relating to the condition, you will also have to learn how to cope with the physiological and emotional issues that follow. Keep in mind that it is OK to feel shocked and...

• Am I at Risk for Developing Breast Cancer?

  Breast cancer is identified to be a major killer of middle-aged women, and the second most common cause of death by cancer. It is estimated that one out of every eight  American women living up to 95-years-old develop breast cancer. The number of deaths from breast carcinoma is now declining due to...

• 22 Year Old Battles Non-Traditional Ovarian Cancer for Second Time

  Everyone who has had their own battle with cancer is a hero, and those who have had to deal with it more than once are some of the strongest warriors. At only 22 years old, Megan Santa Croce is fighting against a non-traditional form of ovarian cancer for the second time in her life. ...